Navigation Links
Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
Date:2/11/2009

--Preliminary Data from Ongoing Study Shows Seven of 14 Evaluable Patients Achieved Objective Tumor Response by the End of Two Treatment Cycles--

--Bavituximab Has Now Produced Positive Early Results in All Three Ongoing Phase II Combination Therapy Cancer Trials--

TUSTIN, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that its lead product candidate bavituximab achieved the pre-specified Stage A primary endpoint in an ongoing Phase II clinical trial in patients with advanced breast cancer. The Phase II trial is an open-label, Simon two-stage design to evaluate the safety and efficacy of bavituximab in combination with the chemotherapy drugs carboplatin and paclitaxel in locally advanced or metastatic breast cancer patients. Fourteen of the 15 patients enrolled in Stage A were deemed evaluable for tumor response, with seven patients achieving an objective response by approximately eight weeks, after completing two treatment cycles. Six of the patients achieved partial tumor responses and one patient achieved a complete tumor response, according to RECIST criteria.

With the Stage A pre-specified primary endpoint achieved, the design of the clinical trial allows for an additional 31 study patients to be enrolled.

"We have now achieved early success in all of our ongoing Phase II bavituximab cancer trials, surpassing our pre-specified primary endpoint criteria for the number of patients achieving an objective tumor response in each of the three clinical studies, " said Steven W. King, president and CEO of Peregrine. "The results reported today reinforce the positive early data seen in our Phase II breast cancer trial assessing bavituximab in combination with docetaxel, as well as the promising early data we reported last week from our Pha
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... According to a study published today in PLOS ... world where malaria is common can mount an immune ... them to avoid repeated bouts of high fever and ... in their bloodstream. The findings may help researchers develop ... by the malaria parasite. , Each year, approximately 200 ...
(Date:4/17/2014)... University of California, San Diego School of Medicine report ... suffered a recent major loss are more likely to ... The study is published in this month,s issue of ... Because compassionate behaviors are associated with better health and ... into ways to improve the outcomes of individuals whose ...
(Date:4/17/2014)... MANHASSET, NY In a review published in the ... MD, president of The Feinstein Institute for Medical Research, ... the medical community,s approach to treating sepsis, ... 200,000 Americans. , Sepsis occurs when molecules released into ... inflammation throughout the body. Inflammation is necessary for maintaining ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... Health Plans of America (MHPA) Executive Director ... proposed elimination of California,s State Children,s Health Insurance Program ... Governor,s proposal to eliminate the Healthy Families program would ... the federal government has just approved a major expansion ...
... led by conservative political operative with ties to convicted lobbyist ... Public Campaign Action Fund issued a new investigative report today ... group behind the political ads running in eight states, including ... funded by the Americans for Prosperity Foundation, which has a ...
... with ties to convicted lobbyist Jack Abramoff , , ... new investigative report today called "Viewers Beware of Anti-Health Care ... in eight states, including Nebraska, to oppose health care reform. ... which has a record as a right-wing political operation and ...
... Study findings could have lifesaving potential , MONDAY, June ... sleep during colonoscopy results in more frequent detection of ... new research has found. , During colonoscopy, patients can ... kept awake using moderate conscious sedation, which allows them ...
... Reducing Health Risks , , EAU CLAIRE, Wisc., June ... aren,t typically at risk for stroke, but lifestyle habits developed ... program run by Sacred Heart Hospital offers elementary school-aged children ... with parents and the administration at St. Mary,s and St. ...
... , Tate & Lyle will not appeal ITC decision; Voluntarily dismisses ... Changzhou Niutang , one of the largest global ... US Niutang, today announced that Tate & Lyle will not appeal ... decisively rejected Tate & Lyle,s infringement allegations against Niutang ...
Cached Medicine News:Health News:MHPA, Leading Association Representing Medicaid Health Plans, Issues Statement on Proposed California SCHIP Elimination 2Health News:'Viewers Beware' Report by Watchdog Group Exposes Conservative Group Behind Anti-Healthcare Ads Running in Montana 2Health News:'Viewers Beware' Report By Watchdog Group Exposes Conservative Group Behind Anti-Healthcare Ads Running In Nebraska 2Health News:Deep Sleep May Improve Colonoscopy Results 2Health News:Sacred Heart Hospital Starts to Expose Students to Stroke Awareness at an Early Age 2Health News:Niutang Sucralose Patent Litigation Successfully Concluded 2Health News:Niutang Sucralose Patent Litigation Successfully Concluded 3
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... PC captures, displays, replays and analyzes ... proven to be effective in evaluating ... obstructive pulmonary disease.,It provides objective evidence ... , , Waveform and time-expanded ...
... youre faced with the challenge of,controlling ... and timely patient data,management is critical. ... reliable,access to important clinical information,wherever you ... AND GO concept,makes your job easier. ...
... System is a multifunctional hybrid configuration, ... Accelerator and a SOMATOM CT Scanner ... image guidance to radiation treatment delivery, ... within the treatment room. The Siemens ...
... a web-enabled PACS that has built-in ... workflow integration. It is a multi-modality ... archives images, reports and clinical data ... non-DICOM devices and gives Cardiologists a ...
Medicine Products: